| Item Type | Name |
|
Concept
|
Proto-Oncogene Proteins c-met
|
|
Academic Article
|
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
|
|
Academic Article
|
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
|
|
Academic Article
|
Role of receptor tyrosine kinases in lung cancer.
|
|
Academic Article
|
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
|
|
Academic Article
|
Therapeutic targeting of the receptor tyrosine kinase Met.
|
|
Academic Article
|
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
|
|
Academic Article
|
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
|
|
Academic Article
|
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
|
|
Academic Article
|
Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
|
|
Academic Article
|
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
|
|
Academic Article
|
c-Met inhibition.
|
|
Academic Article
|
c-Met: structure, functions and potential for therapeutic inhibition.
|
|
Academic Article
|
c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.
|
|
Academic Article
|
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
|
|
Academic Article
|
MET as a target for treatment of chest tumors.
|
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
|
Academic Article
|
Expression and mutational analysis of MET in human solid cancers.
|
|
Academic Article
|
MET pathway as a therapeutic target.
|
|
Academic Article
|
Role of c-Met in cancer: emphasis on lung cancer.
|
|
Academic Article
|
PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.
|
|
Academic Article
|
MET receptor tyrosine kinase.
|
|
Academic Article
|
Ethnic differences and functional analysis of MET mutations in lung cancer.
|
|
Academic Article
|
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
|
|
Academic Article
|
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.
|
|
Academic Article
|
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
|
|
Academic Article
|
Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin.
|
|
Academic Article
|
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells.
|
|
Academic Article
|
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.
|
|
Academic Article
|
Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion.
|
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
|
Academic Article
|
PAX3 and SOX10 activate MET receptor expression in melanoma.
|
|
Academic Article
|
MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.
|
|
Academic Article
|
MET and phosphorylated MET as potential biomarkers in lung cancer.
|
|
Academic Article
|
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
|
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
|
Academic Article
|
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
|
|
Academic Article
|
Tyrosine kinase mutations in human cancer.
|
|
Academic Article
|
c-Met is a potentially new therapeutic target for treatment of human melanoma.
|
|
Academic Article
|
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.
|
|
Academic Article
|
Review of clinic trials: agents targeting c-Met.
|
|
Academic Article
|
MET molecular mechanisms and therapies in lung cancer.
|
|
Academic Article
|
Personalized treatment of lung cancer.
|
|
Academic Article
|
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
|
|
Academic Article
|
Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer.
|
|
Academic Article
|
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin.
|
|
Academic Article
|
C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes.
|
|
Academic Article
|
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
|
|
Academic Article
|
Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung.
|
|
Academic Article
|
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
|
|
Academic Article
|
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
|
|
Academic Article
|
Role of MetMAb (OA-5D5) in c-MET active lung malignancies.
|
|
Academic Article
|
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.
|
|
Academic Article
|
Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis.
|
|
Academic Article
|
MET as a possible target for non-small-cell lung cancer.
|
|
Academic Article
|
Critical role of S1PR1 and integrin ß4 in HGF/c-Met-mediated increases in vascular integrity.
|
|
Academic Article
|
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
|
|
Academic Article
|
Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function.
|
|
Academic Article
|
Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells.
|
|
Academic Article
|
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.
|
|
Academic Article
|
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
|
|
Academic Article
|
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
|
|
Academic Article
|
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer.
|
|
Academic Article
|
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
|
|
Academic Article
|
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
|
|
Academic Article
|
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
|
|
Academic Article
|
MET as a drug target.
|
|
Academic Article
|
C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.
|
|
Academic Article
|
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
|
|
Academic Article
|
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
|
|
Academic Article
|
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
|
|
Academic Article
|
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
|
|
Academic Article
|
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
|
|
Academic Article
|
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
|
|
Academic Article
|
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors.
|
|
Academic Article
|
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
|
|
Academic Article
|
MET receptor in oncology: From biomarker to therapeutic target.
|
|
Academic Article
|
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report.
|
|
Grant
|
Role of c-Met in SCLC and Potential for Novel Therapy
|
|
Grant
|
Novel Targeted Therapy in Pancreatic Cancer
|